Abstract
Current evidence suggests that angiotensin II may be involved in the regulation of renal erythropoietin (EPO) production. The present study assessed the role of angiotensin II (A II) in different doses in the control of EPO production in humans. In a parallel, randomized, placebo-controlled open design, 60 healthy male volunteers received a 6-h intravenous infusion of: placebo (placebo, electrolyte solution), a pressor dose of A II (1–3 µg/min; A II press), a combination of a pressor dose of A II and the selective AT1-receptor blocker losartan, 50 mg (A II press + L), a subpressor dose of A II (0.0375–0.15 µg/min; A II subpress) and a combination of a subpressor dose of A II and losartan (A II subpress + L). A II press treatment resulted in a significant increase of the maximum EPO concentration (C maxEPO, 41% higher versus placebo) and the amount of EPO produced in 24 h (AUCEPO(0–24 h), 61% larger versus placebo), A II subpress treatment increased C maxEPO (35% higher versus placebo) and AUCEPO(0–24 h) (34% larger versus placebo). A II press + L and A II subpress + L treatments did not significantly increase C maxEPO and AUCEPO(0–24 h) compared to placebo. A II affects EPO production in a dose-dependent manner. The signal seems to be mediated via AT1-receptors. A II appears to be one modulator EPO production in humans.
Similar content being viewed by others
Author information
Authors and Affiliations
Additional information
Received after revision: 7 December 1999
Electronic Publication
Rights and permissions
About this article
Cite this article
Freudenthaler, S., Lucht, I., Schenk, T. et al. Dose-dependent effect of angiotensin II on human erythropoietin production. Pflügers Arch – Eur J Physiol 439, 838–844 (2000). https://doi.org/10.1007/s004249900238
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s004249900238